{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for clindamycin root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
Possibly Marketed Outside US
Source:
M020
(2024)
Source URL:
First approved in 2024
Source:
M020
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M005
(2024)
Source URL:
First approved in 2024
Source:
M005
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M020
(2024)
Source URL:
First approved in 2019
Source:
M018
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2019)
Source URL:
First approved in 2019
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2016)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02234869: Phase 4 Interventional Withdrawn Relapsing Multiple Sclerosis
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
NUCLEIC ACID
Status:
Investigational
Source:
INN:rubravameran [INN]
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Class:
NUCLEIC ACID
Status:
Investigational
Class:
NUCLEIC ACID
